Session Learning Objectives 

Upon completion of this activity, participants will: 

Have increased knowledge regarding the 

• - Criteria used to determine if a patient should be assessed for high risk of breast cancer  
  - Models used to assess breast cancer risk 
• - Relationship between breast density and breast cancer risk 
  - Predictive value of BI-RADS® 
• - Role of contrast-enhanced mammography in breast cancer screening 

Have greater confidence in their ability to  

• - Incorporate interprofessional strategies into breast cancer care 

Session Learning Objectives 

Upon completion of this activity, participants will: 

• Have increased knowledge regarding the 
  
  - Comparability of PET images for assessment of treatment response 
  - Clinical data evaluating ER-targeting and PET tracers in ILC 
  - Diagnostic potential of artificial intelligence 
  - Utilization of radiomics and radiogenomics to characterize tumors for more precise imaging and treatment 

• 
  Have greater confidence in their ability to 
  
  - Incorporate interprofessional strategies into breast cancer care 

Session Learning Objectives 

After completion of this activity, participants will 

• Have increased knowledge regarding the  

•  

• - Differences among genomic assays available to patients with HR-positive early breast cancer 

  - Clinical data supporting the use of adjuvant therapies in early HR-positive early breast cancer 
•  
• Have greater competence related to 
•  

• - Mitigation of adverse events that present for patients receiving therapy for HR-positive early breast cancer 

•  

• Have greater confidence in their ability to incorporate interprofessional strategies into breast cancer care 

Session Learning Objectives 

Upon completion of this activity, participants will: 

• Have increased knowledge regarding the  

•  

• - Mechanism of action of oral SERDs  

• - Clinical trial data associated with other endocrine therapies of consideration for the care of patients with advanced/metastatic HR-positive breast cancer 

• - Clinical trial data about CKD4/6 inhibitors in the advanced/metastatic HR-positive breast cancer 

•  

• Have greater confidence in their ability to incorporate interprofessional strategies into breast cancer care 

Session Learning Objectives 

• Have increased knowledge regarding the  

•  

• - Therapeutic opportunities targeting mutations of consideration in patients with HR-positive breast cancer  

• - Mechanism of actions of antibody drug conjugates 

•  

• Have greater competence related to 

• - Managing toxicities associated with therapies used in HR-positive breast cancer 

•  

• Have greater confidence in their ability to incorporate interprofessional strategies into breast cancer care 

Session Learning Objectives 

Upon completion of this activity, participants will 

• Have increased knowledge regarding the  

• - Clinical data associated with treatment strategies for pre-operative treatment of HER2-positive breast cancer 
  - Definition of high-risk residual HER2-positive breast cancer 

• - Escalation and de-escalation strategies in HER2-positive early breast cancer  

•  

• Have greater confidence in their ability to incorporate interprofessional strategies into breast cancer care 

Session Learning Objectives 

Upon completion of this activity, participants will 

• Have increased knowledge regarding the  
  
  - Clinical data associated with emerging HER2-directed antibody drug conjugates for the treatment of HER2-positive breast cancer 
  - Clinical data associated with emerging novel therapies for the treatment of HER2-positive breast cancer 

•  

• Have greater competence related to 

• 
  - Selecting the appropriate treatments for patients with metastatic HER2-positive breast cancer 

• - Managing toxicities associated with therapies used in HER2-positive breast cancer 
  
  Have greater confidence in their ability to incorporate interprofessional strategies into breast cancer care 

Session Learning Objectives 

Upon completion of this activity, participants will: 

• Have increased knowledge regarding the  
   
  - Interpretation of testing results to determine therapeutic approaches for patients  

  - Emerging opportunities targeting HER2-low patients with breast cancer 
  
  Have greater competence related to 
•  

• - Utilizing the overall prognosis of a patient with HER2-positive brain metastases to develop a treatment plan 
  
  Have greater confidence in their ability to incorporate interprofessional strategies into breast cancer care 

Session Learning Objectives 

Upon completion of this activity, participants will: 

• Have increased knowledge regarding the  
  
  - Clinical data associated with the impact of ctDNA in early-stage triple negative breast cancer  

•  

• Have greater competence related to 
   

• - Selecting the appropriate systemic therapy for patients with early-stage triple negative breast cancer 
  - Mitigation of adverse events that present for patients receiving therapy for early-stage triple negative breast cancer 

•  

• Have greater confidence in their ability to incorporate interprofessional strategies into breast cancer care 

Session Learning Objectives 

Upon completion of this activity, participants will: 

• Have increased knowledge regarding  
  
  - Clinical trials investigating emerging small molecules in metastatic triple negative breast cancer 
  - Emerging data related to novel therapies for the management of patients with metastatic triple negative breast cancer 
  - Concerns associated with brain metastases in triple negative breast cancer 

•  

• Have greater competence related to 
   

• - Incorporating guideline-based decision making into the development of treatment plans for patients with metastatic triple negative breast cancer 
  - Incorporating shared decision into the development of treatment plans for patients with breast cancer 

• 
  Have greater confidence in their ability to incorporate interprofessional strategies into breast cancer care